Overview

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with refractory solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Children's Hospital Los Angeles

Treatments:

Bevacizumab
Camptothecin
Dacarbazine
Irinotecan
Temozolomide
Vincristine